PMID- 35356504
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220401
IS  - 2296-875X (Print)
IS  - 2296-875X (Electronic)
IS  - 2296-875X (Linking)
VI  - 9
DP  - 2022
TI  - Correlation of Serum CysC, IMA, and LP-PLA2 Levels With Type 2 Diabetes Mellitus 
      Patients With Lower Extremity Atherosclerotic Occlusive Disease.
PG  - 846470
LID - 10.3389/fsurg.2022.846470 [doi]
LID - 846470
AB  - OBJECTIVE: To investigate the serum level of cystatin C (CysC), ischemia-modified 
      albumin (IMA), and lipoprotein-associated phospholipase A2 (LP-PLA2) in patients 
      with type 2 diabetes mellitus (T2DM) and with lower extremity atherosclerotic 
      occlusive disease (LEASOD) and their correlation. METHODS: From March 2017 to 
      December 2019, 110 patients with T2DM with LEASOD, who were treated in our 
      hospital, were selected as the observation group. One hundred ten healthy persons 
      who received medical examination in our hospital during the same period were 
      selected as the control group. Serum CysC, IMA, LP-PLA2, and ankle-brachial index 
      (ABI) were detected in each group. According to the ABI index, the observation 
      group was divided into three subgroups, namely, the mild group (n = 45), the 
      moderate group (n = 42), and the severe group (n = 23). Pearson correlation 
      analysis was used to analyze the relationship between serum CysC, IMA, and 
      LP-PLA2 levels in patients with T2DM with LEASOD and their condition. The 
      receiver operator characteristic (ROC) curve was used to analyze the diagnostic 
      value of serum CysC, IMA, and LP-PLA2 levels in patients with T2DM with LEASOD. 
      RESULTS: The serum levels of CysC, IMA, and LP-PLA2 in the observation group were 
      higher than those in the control group (p < 0.05). The serum levels of CysC, IMA, 
      and LP-PLA2 in the severe and the moderate group were higher than those in the 
      mild group, and the serum levels of CysC, IMA, and LP-PLA2 in the severe group 
      were higher than those in the moderate group (p < 0.05). Pearson correlation 
      analysis showed that CysC, IMA, and LP-PLA2 levels were all negatively correlated 
      with ABI (r = -0.802, r = -0.757, r = -0.764, p < 0.001). The ROC curve results 
      showed that the area under the curve (AUC) of serum CysC in the diagnosis of T2DM 
      with LEASOD was 0.806, and the best cut-off value was 1.74 mg/L. The AUC of serum 
      IMA for diagnosis of T2DM with LEASOD was 0.772, and the best cut-off value was 
      92.58 g/L. The AUC of serum LP-PLA2 in the diagnosis of T2DM with LEASOD was 
      0.781, and the best cut-off value was 544.86 ng/L. The AUC of the three combined 
      diagnoses of T2DM with LEASOD was 0.863. CONCLUSION: Serum levels of CysC, IMA, 
      and LP-PLA2 were increased in patients with T2DM with LEASOD. Serum CysC, IMA, 
      and LP-PLA2 are closely related to the severity of the disease. The higher the 
      serum levels of CysC, IMA, and LP-PLA2, the more serious the degree of lower 
      extremity arteriosclerosis occlusion, which can be used as an important serum 
      marker to monitor the severity of T2DM with LEASOD. The combined detection of 
      serum CysC, IMA, and LP-PLA2 has good diagnostic value for patients with T2DM 
      with LEASOD.
CI  - Copyright (c) 2022 Feng, Chen, Wang, Huang, Zhu and Zhou.
FAU - Feng, Fen
AU  - Feng F
AD  - School of Pharmacy, Shaoyang University, Shaoyang, China.
FAU - Chen, Yong
AU  - Chen Y
AD  - Department of Oncology and Hematology, The Central Hospital of Shaoyang, 
      Shaoyang, China.
FAU - Wang, Gang
AU  - Wang G
AD  - Department of Endocrinology, The Central Hospital of Shaoyang, Shaoyang, China.
FAU - Huang, Ping
AU  - Huang P
AD  - Department of Endocrinology, The Central Hospital of Shaoyang, Shaoyang, China.
FAU - Zhu, Qiaolin
AU  - Zhu Q
AD  - Department of Endocrinology, The Central Hospital of Shaoyang, Shaoyang, China.
FAU - Zhou, Bin
AU  - Zhou B
AD  - Department of Endocrinology, The Central Hospital of Shaoyang, Shaoyang, China.
LA  - eng
PT  - Journal Article
DEP - 20220309
PL  - Switzerland
TA  - Front Surg
JT  - Frontiers in surgery
JID - 101645127
PMC - PMC8959309
OTO - NOTNLM
OT  - correlation
OT  - cystatin C
OT  - ischemia modified albumin
OT  - lipoprotein phospholipase A2
OT  - lower extremity atherosclerotic occlusive disease
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/04/01 06:00
MHDA- 2022/04/01 06:01
PMCR- 2022/03/09
CRDT- 2022/03/31 05:32
PHST- 2021/12/31 00:00 [received]
PHST- 2022/01/21 00:00 [accepted]
PHST- 2022/03/31 05:32 [entrez]
PHST- 2022/04/01 06:00 [pubmed]
PHST- 2022/04/01 06:01 [medline]
PHST- 2022/03/09 00:00 [pmc-release]
AID - 10.3389/fsurg.2022.846470 [doi]
PST - epublish
SO  - Front Surg. 2022 Mar 9;9:846470. doi: 10.3389/fsurg.2022.846470. eCollection 
      2022.